Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06051890 · ClinicalTrials.gov registry record · Phase 4
Assessing Optimal XRB Initiation Points in Jail
A Phase 4 study of Opioid Use Disorder, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT06051890 is a Phase 4 study of Opioid Use Disorder that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 200 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06051890, a Phase 4 study of Opioid Use Disorder, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.
Conditions Studied
Interventions
- DRUG Extended-Release Buprenorphine (XRB)
- DRUG Sublingual Buprenorphine (SLB)
Study Locations (4)
Massachusetts
- Tufts University Health Sciences - Boston
- Baystate Health - Springfield
New Jersey
- Middlesex County House of Corrections - New Brunswick
New York
- NYU Langone Health - 180 Madison Ave - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-02 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06051890
The ClinicalTrials.gov registry entry for NCT06051890 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Extended-Release Buprenorphine (XRB) is the first listed.
NCT06051890 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT06051890 about?
NCT06051890 is a clinical study titled "Assessing Optimal XRB Initiation Points in Jail". This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducte...
What is the current status of trial NCT06051890?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-06-02. Estimated completion is 2027-03-01.
What conditions does trial NCT06051890 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06051890?
The interventions under investigation include: Extended-Release Buprenorphine (XRB) (DRUG), Sublingual Buprenorphine (SLB) (DRUG).
Who is sponsoring clinical trial NCT06051890?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06051890 being conducted?
This trial has 4 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
RECRUITING · Phase 4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
RECRUITING · Phase 4
-
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.